Blood transfusion is an indispensable cell therapy. Red blood cell (RBC) transfusion depends on the availability of donor material, and concerns over supply and safety have spurred development of methods to manufacture blood from stem cells. Recent advances have increased excitement about the potential therapeutic production of RBCs ex vivo. Current methods could theoretically yield therapeutic doses of RBCs. However, generation of RBCs in the large numbers required for transfusion remains a significant challenge. In this article, we review the recent progress made in producing RBCs from various cell sources for transfusion purposes and discuss the most compelling issues to be addressed to translate this progress into a clinical-grade transfusion product. It is hoped that ongoing efforts and new technologies for ex vivo erythrocytes generation will provide alternative transfusion products to meet present and future clinical requirements.
How to translate text using browser tools
1 August 2013
How Far are Stem-Cell-Derived Erythrocytes from the Clinical Arena?
Xiaolei Li,
Zhiqiang Wu,
Xiaobing Fu,
Weidong Han
ACCESS THE FULL ARTICLE
It is not available for individual sale.
This article is only available to subscribers.
It is not available for individual sale.
It is not available for individual sale.
![](/ContentImages/journals/bisi/63/8/8/WebImages/012.063.0800.cover.jpg)
BioScience
Vol. 63 • No. 8
August 2013
Vol. 63 • No. 8
August 2013
erythrocyte
ex vivo RBC
pluripotent stem cell
regenerative medicine
transfusion product